Healthpoint Biotherapeutics today announced that the results of a 24-week open-label follow-up to the HP802-247 Phase 2b trial will be presented by Robert Kirsner, MD, PhD, on Friday, July 27, 2012, from 3:55- 4:15 pm, during the American College of Wound Healing and Tissue Repair held at the Swissotel in Chicago.